Clinical Research Directory
Browse clinical research sites, groups, and studies.
Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Summary
The study aims to assess the direct patient-reported perception (PROs) of individuals affected by IDH-mutant, grade 2 gliomas undergoing radiotherapy or pharmacological treatment with vorasidenib. To evaluate quality of life, perception of treatment-related symptoms, and anxiety levels during therapy by comparing patients receiving radiotherapy with those receiving pharmacological treatment with vorasidenib. The control group will consist of patients with IDH-mutant, grade 2 gliomas who are under clinical and radiological follow-up only. To assess the feasibility of using PROMs in routine clinical practice. To analyze patient-reported critical issues in order to qualitatively improve care pathways.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
90
Start Date
2025-04-23
Completion Date
2027-10
Last Updated
2026-04-23
Healthy Volunteers
No
Interventions
Vorasidenib
patients receiving pharmacological treatment with vorasidenib, isocitrate dehydrogenase (IDH) inhibitor;
Radiotherapy
Radiotherapy: patients treated with radiotherapy for residual disease or recurrence;
active surveillance
Follow-up: patients undergoing active surveillance with periodic follow-up including MRI and clinical evaluation.
Locations (1)
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy